Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI.
Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane?
Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
